欧普拉西亚制药公司在2026年第一季度每股损失0.37美元,错过了估计并引发"强销售"下调尽管基于长期潜力的一些买入评级. Eupraxia Pharmaceuticals lost $0.37 per share in Q1 2026, missing estimates and triggering a "strong sell" downgrade despite some buy ratings based on long-term potential.

欧普拉西亚制药公司报告2026年第一季度每股亏损0.37美元,估计缺失了0.21美元,促使扎克斯研究将该股票从"持有"降级为"强销售". Eupraxia Pharmaceuticals reported a Q1 2026 loss of $0.37 per share, missing estimates by $0.21, prompting Zacks Research to downgrade the stock to "strong sell" from "hold." 尽管包括HC Wainwright和Lifesci Capital在内的一些分析师维持了基于长期潜力的"买入"或"强购"评级, 但经修订的利预测显示短期亏损增加. Despite some analysts, including HC Wainwright and Lifesci Capital, maintaining "buy" or "strong-buy" ratings based on long-term potential, revised earnings forecasts show increased near-term losses. 公司正在开发一期狼治疗, 市值为2.7亿美元,交易价7.51美元, P/E负比为-7.29. The company, developing a lupus therapy in Phase 1 trials, has a market cap of $270 million and trades at $7.51 with a negative P/E of -7.29. 分析师的评级仍然是"适度购买",目标为15美元. The consensus analyst rating remains "moderate buy" with a $15.00 target.